AN INTERVENTIONAL, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 1/2/3 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b RNA-BASED VACCINE CANDIDATES IN COVID-19 VACCINE-EXPERIENCED HEALTHY INDIVIDUALS
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors BioNTech
Most Recent Events
- 10 Apr 2024 Status changed from active, no longer recruiting to completed.
- 28 Nov 2023 Results (n= 727) of trial evaluating the safety, tolerability and immunogenicity of BNT162b, RNA-based SARS-CoV-2 vaccine candidates given as a booster dose in adults to prevent COVID-19 published in the Clinical Infectious Diseases.
- 23 Oct 2023 Planned End Date changed from 26 Mar 2024 to 19 Mar 2024.